


## PHARMACEUTICAL 2021

## Urovant Sciences Ltd. Rank 373 of 409





## PHARMACEUTICAL 2021

## Urovant Sciences Ltd. Rank 373 of 409

The relative strengths and weaknesses of Urovant Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Urovant Sciences Ltd. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 305% points. The greatest weakness of Urovant Sciences Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 316% points.

The company's Economic Capital Ratio, given in the ranking table, is -714%, being 360% points below the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	58,318
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,931
Liabilities, Non-Current	3,086
Other Assets	3,767
Other Compr. Net Income	183
Other Expenses	65
Other Liabilities	87,284
Other Net Income	-7,944
Property and Equipment	1,210
Research and Development	92,437
Revenues	0
Selling, General and Administrative Expense	46,299

Output Variable	Value in 1000 USD
Assets	63,295
Liabilities	121,301
Expenses	138,801
Stockholders Equity	-58,006
Net Income	-146,745
Comprehensive Net Income	-146,654
Economic Capital Ratio	-714%